(Q36150517)

12 August 2017

1 reference

title

Dendritic cell fusion vaccines for cancer immunotherapy (English)

1 reference

12 August 2017

1 reference

1 reference

Jacalyn Rosenblatt

1

1 reference

12 August 2017

Donald Kufe

series ordinal

2

1 reference

12 August 2017

David Avigan

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

703-715

1 reference

Human tumor antigens recognized by T lymphocytes

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

The first 1000 dendritic cell vaccinees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cells: development, function and potential use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Manipulating dendritic cell biology for the active immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cells: immunobiology and cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Distinct dendritic cell subsets differentially regulate the class of immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Therapeutic immune response induced by electrofusion of dendritic and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.703

21 January 2018

Identifiers

DOI

10.1517/14712598.5.5.703

1 reference

12 August 2017

1 reference